Related references
Note: Only part of the references are listed.Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer
Stephan B. Dreyer et al.
GASTROENTEROLOGY (2021)
PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer
S. B. Dreyer et al.
CLINICAL ONCOLOGY (2020)
Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer
Naim U. Rashid et al.
CLINICAL CANCER RESEARCH (2020)
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Keith T. Flaherty et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Michael J. Pishvaian et al.
LANCET ONCOLOGY (2020)
Pan-cancer analysis of whole genomes
Peter J. Campbell et al.
NATURE (2020)
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al.
NATURE (2020)
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
Michelle Chan-Seng-Yue et al.
NATURE GENETICS (2020)
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Grainne M. O'Kane et al.
CLINICAL CANCER RESEARCH (2020)
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer
Holly Brunton et al.
CELL REPORTS (2020)
The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities
Won Jin Ho et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The National Lung Matrix Trial of personalized therapy in lung cancer
Gary Middleton et al.
NATURE (2020)
Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes
Koji Miyabayashi et al.
CANCER DISCOVERY (2020)
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
Hemant M. Kocher et al.
NATURE COMMUNICATIONS (2020)
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilie et al.
CLINICAL CANCER RESEARCH (2019)
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers
Aatur D. Singhi et al.
GASTROENTEROLOGY (2019)
Molecular subtypes of pancreatic cancer
Eric A. Collisson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine
Gwen Lomberk et al.
NATURE COMMUNICATIONS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer
Masayuki Kitano et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Harnessing DNA Double-Strand Break Repair for Cancer Treatment
Anika Trenner et al.
FRONTIERS IN ONCOLOGY (2019)
Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling
Stephan B. Dreyer et al.
CHINESE CLINICAL ONCOLOGY (2019)
Dissecting the molecular landscape of pancreatic cancer: towards a precision medicine approach
Antonio Pea et al.
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT (2019)
Tumor Heterogeneity in Pancreatic Adenocarcinoma
Jerome Cros et al.
PATHOBIOLOGY (2018)
The emerging clinical relevance of genomics in cancer medicine
Michael F. Berger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Andrew J. Aguirre et al.
CANCER DISCOVERY (2018)
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Herve Tiriac et al.
CANCER DISCOVERY (2018)
Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma
Zhi Rong Qian et al.
JAMA ONCOLOGY (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer (Reprinted from vol 218, pg 39-50, 2017)
Eveline E. Vietsch et al.
CANCER GENETICS (2018)
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
Kyaw L. Aung et al.
CLINICAL CANCER RESEARCH (2018)
GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer
Paola Martinelli et al.
GUT (2017)
DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development
Talia Golan et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma
Michael E. Feigin et al.
NATURE GENETICS (2017)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
Ashton A. Connor et al.
JAMA ONCOLOGY (2017)
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2017)
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Andrew J. Aguirre et al.
CANCER CELL (2017)
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Stephan B. Dreyer et al.
CLINICAL CANCER RESEARCH (2017)
Implementing Genome-Driven Oncology
David M. Hyman et al.
CELL (2017)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
H. S. Rugo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
Lorraine A. Chantrill et al.
CLINICAL CANCER RESEARCH (2015)
Patient-centric trials for therapeutic development in precision oncology
Andrew V. Biankin et al.
NATURE (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Richard A. Moffitt et al.
NATURE GENETICS (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Diagnostic Accuracy of Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytology of Pancreatic Lesions
Hae Woon Baek et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2015)
Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)
Elizabeth L. Cureton et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin
Katherine A. Hoadley et al.
CELL (2014)
Pancreatic cancer genomics
David K. Chang et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2014)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Clinical and molecular characterization of HER2 amplified-pancreatic cancer
Angela Chou et al.
GENOME MEDICINE (2013)
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
J. Harder et al.
BRITISH JOURNAL OF CANCER (2012)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Andrew V. Biankin et al.
NATURE (2012)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
International network of cancer genome projects
Thomas J. Hudson et al.
NATURE (2010)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
H Safran et al.
CANCER INVESTIGATION (2004)
Share Paper
